leadf
logo-loader
AIM:ONC

Oncimmune

Receive alerts
Market:
AIM
Market Cap:
£94.99 m
Price
149.50 GBX
Change
0.00%
52 weeks high
163.91
52 weeks low
30.00

In brief

Oncimmune's range of diagnostic tests profile the body’s immune response to detect evidence of the body’s natural response to cancer, which can detect cancer on average four years earlier than standard clinical diagnosis. 

Snapshot

  • EarlyCDT test met primary endpoint in lung cancer study
  • Has European CE mark approval for the EarlyCDT- Lung test
  • Deal with US firm for EarlyCDT

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Oncimmune is building momentum in key areas says broker finnCap

The City broker's forecasts are unchanged, while it has reiterated its 150p share price target

on 4/6/20